Table 4.
Analysis of polyunsaturated fatty acids before and after insulin analog initiation therapy
| Parameter | Before treatment (mean ± SD) | After treatment (mean ± SD) | n | p value |
|---|---|---|---|---|
|
DGLA (C20:3n6) (μg/ml) |
44.11 ± 13.97 |
60.84 ± 10.72* |
16 |
<0.001 |
|
AA (C20:4n6) (μg/ml) |
100.10 ± 23.28 |
117.65 ± 24.66* |
16 |
0.018 |
|
EPA (C20:5n3) (μg/ml) |
3.98 ± 3.09 |
5.07 ± 2.25* |
16 |
0.004 |
|
DHA (C22:6n3) (μg/ml) |
31.33 ± 13.31 |
38.16 ± 11.66 * |
16 |
<0.001 |
|
AA/DHA |
3.47 ± 1.08 |
3.23 ± 0.77 |
16 |
0.065 |
| AA/EPA | 31.28 ± 11.76 | 25.34 ± 7.88* | 16 | 0.006 |
DGLA, Dihomo-gamma-linolenic acid; AA, Arachidonic acid; EPA, Eicosapentaenoic acid; DHA, Docosahexaenoic acid.